Pyk2 plays a critical role in synaptic dysfunction during the early stages of Alzheimer’s disease

The locus of the gene PTK2B encoding the tyrosine kinase Pyk2 has been associated with the risk of late-onset Alzheimer’s disease, the predominant form of dementia. Pyk2 is primarily expressed in neurons where it is involved in excitatory neurotransmission and synaptic functions. Although previous studies have implicated Pyk2 in amyloid-β and Tau pathologies of Alzheimer’s disease, its exact role remains unresolved, with evidence showing both detrimental and protective effects in mouse models. Here, we investigate the role of Pyk2 in hippocampal hyperactivity, Tau synaptic localization and synaptic loss associated with Alzheimer’s disease-related alterations occurring in the early stages of the disease. Pyk2’s involvement in amyloid-β oligomer-induced hippocampal neuronal hyperactivity was investigated using whole-cell patch clamp in hippocampal slices from WT and Pyk2 KO mice. Various Pyk2 mutants were overexpressed in cultured cortical neurons to study Pyk2’s role in synaptic loss. Pyk2 and Tau interaction was assessed with bimolecular fluorescence complementation assays in cultured neurons and co-immunoprecipitation in mouse cortex. To evaluate the impact of Pyk2 on Tau expression in synapses, cellular fractionation was performed on hippocampi from WT and Pyk2 KO mice. Genetic deletion of Pyk2 prevented amyloid-β oligomer-induced hippocampal neuronal hyperactivity and synaptic loss. Overexpression of Pyk2 in neurons decreased dendritic spine density independently of its autophosphorylation or kinase activity, but through its proline-rich motif 1. Furthermore, Pyk2 interacted with Tau in synapses, while Pyk2 deletion decreased Tau synaptic localization in the hippocampus. Pyk2 contributes to hippocampal neuronal hyperactivity and synaptic loss, two early events in Alzheimer’s disease pathogenesis. It is also involved in Tau synaptic localization, a process known to be detrimental in Alzheimer’s disease. These findings highlight Pyk2 as a critical player in Alzheimer’s disease pathophysiology and suggest its potential as a promising therapeutic target for early intervention.